EUCTR2020-004535-24-DE
Active, not recruiting
Phase 1
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and other Advanced Solid Tumors - First-in-Human Study of RLY-4008 in patients with ICC and other advanced solid tumors
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Relay Therapeutics, Inc.
- Enrollment
- 550
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Main inclusion criteria for the study, including specific criteria for Part 1, 2 and 3 can be found in the study protocol (section 5\.2\).
- •14\. Patient is currently receiving RLY\-4008 on RLY\-4008\-101 Study and benefiting from treatment as assessed by the investigator.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 363
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 187
Exclusion Criteria
- •Main exclusion criteria for the study, including specific criteria for Part 1, 2 and 3 can be found in the study protocol (section 5\.3\).
- •21\. Patient has permanently discontinued treatment with RLY\-4008 for any reason before enrolling into Part 4\.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid TumorsBile Duct CancerIntrahepatic Bile Duct Carcinoma10019815NL-OMON54283Relay Therapeutics, Inc.4
Active, not recruiting
Phase 1
A study to investigate the effects of study drug RLY-4008 in patients with Intrahepatic Cholangiocarcinoma and other Advanced Solid TumorsEUCTR2020-004535-24-NLRelay Therapeutics, Inc.550
Active, not recruiting
Phase 1
A study to investigate the effects of study drug RLY-4008 in patients with Intrahepatic Cholangiocarcinoma and other Advanced Solid TumorsEUCTR2020-004535-24-SERelay Therapeutics, Inc.550
Active, not recruiting
Phase 1
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid TumorsFGFR2 AmplificationFGFR2 Gene MutationFGFR2 Gene Fusion/RearrangementFGFR2 Gene TranslocationFGFR2 Gene ActivationIntrahepatic CholangiocarcinomaCholangiocarcinomaOther Solid Tumors, AdultNCT04526106Elevar Therapeutics540
Terminated
Phase 1
A Phase 1/2 study to determine the effect of Doxorubicin loaded EnGeneIC Delivery Vehicles on progression free survival in Patients with Recurrent Glioblastoma Multiforme (GBM)Recurrent Glioblastoma MultiformeCancer - BrainACTRN12613000297729EnGeneIC Ltd46